The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Selecting between anti-CD20 bispecific antibodies and anti-CD19 CAR T-cells in third-line NHL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, discusses the role of anti-CD20 bispecific antibodies in treating non-Hodgkin lymphoma (NHL) and their sequencing with anti-CD19 CAR T-cells. Both are approved for third-line therapy. Dr Kamdar usually selects CAR T-cells in this setting due to longer follow-up data, proven central nervous system (CNS) efficacy, and concerns that using bispecific antibodies first might lead to T-cell exhaustion, reducing the effectiveness of subsequent CAR T-cell treatment. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
